Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.46 |
| ▸ | CTSK | P43235 | 13/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16286150 | 0.86 | MEN1 (0.56) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL25319648 | 0.86 | CTSS (0.48) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL8357414 | 0.86 | CTSK (0.61) | CTSSCTSK | |
| SCHEMBL25319652 | 0.86 | CTSS (0.48) | CTSSCTSKCTSLCTSBTDP1 | |
| SCHEMBL16285819 | 0.83 | CTSS (0.50) | CTSSCTSKCTSLCTSBMEN1 | |
| SCHEMBL12602587 | 0.82 | CTSK (0.59) | CTSSCTSKCTSLCTSB | |
| SCHEMBL23453052 | 0.82 | TDP1 (0.45) | CTSSCTSKMEN1GAAKMT2A | |
| SCHEMBL11043865 | 0.81 | CTSK (0.44) | CTSSCTSKCTSLCTSB | |
| SCHEMBL25321787 | 0.80 | CTSS (0.50) | CTSSCTSKCTSLCTSB | |
| SCHEMBL25321785 | 0.80 | CTSS (0.50) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | CTSS 746/4885CTSK 1449/4885CTSL 475/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | CTSS 746/4885CTSK 1449/4885CTSL 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.